Drug Discovery Today 2013 v.18 №09-10

London, UK.: Elsevier. — 96 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Immunogenicity risk management for commercial advantage
Nikolai Schwabe, Victoria LawsonA new approach to assess drug development performance
Alessandro Rosiello, Nicola Dimitri, Filippo FioriniTowards Virtual Knowledge Broker services for semantic integration of life science literature and data sources
Ian Harrow, Wendy Filsell, Peter Woollard, Ian Dix, Michael Braxenthaler, Richard Gedye, David Hoole, Richard Kidd, Jabe Wilson, Dietrich Rebholz-SchuhmannQuantitative characterization of non-contact microdispensing technologies for the sub-microliter range
Stefan Bammesberger, Andreas Ernst, Nadine Losleben, Laurent Tanguy, Roland Zengerle, Peter KoltayTargeting VEGF signalling via the neuropilin co-receptor
Snezana Djordjevic, Paul C. DriscollBrain pericyte plasticity as a potential drug target in CNS repair
Simona Lange, Andrea Trost, Herbert Tempfer, Hans-Christian Bauer, Hannelore Bauer, Eva Rohde, Herbert A. Reitsamer, Robin J.M. Franklin, Ludwig Aigner, Francisco J. RiveraCharacterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools
Nicola Clementi, Nicasio Mancini, Matteo Castelli, Massimo Clementi, Roberto BurioniCrowd computing: using competitive dynamics to develop and refine highly predictive models
Jörg Bentzien, Ingo Muegge, Ben Hamner, David C. ThompsonThe AhR twist: ligand-dependent AhR signaling and pharmaco-toxicological implications
Erwan Guyot, Aline Chevallier, Robert Barouki, Xavier CoumoulTranslational research: the changing landscape of drug discovery
C. Simone FishburnShifting from the single to the multitarget paradigm in drug discovery
José L. Medina-Franco, Marc A. Giulianotti, Gregory S. Welmaker, Richard A. Houghten